Drug Trial Radar · NCT00004832
Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome
Last checked: Nov 20, 2026Latest source record: Mar 25, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Aug 1994
Primary completion
Not stated
Study completion Jun 1998
Sponsor
- Lead sponsor
- FDA Office of Orphan Products DevelopmentFederal agency
- Sponsor type
- Federal agency
- Collaborators
- Duke University
- First posted
- Feb 25, 2000
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
OBJECTIVES: I. Evaluate the safety and effectiveness of 3,4-diaminopyridine (DAP) in the treatment of patients with Lambert-Eaton myasthenic syndrome (LEMS). II. Determine the side-effects and benefits associated with DAP.
Conditions
- Lambert-Eaton Myasthenic Syndrome
Interventions
3,4-diaminopyridineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.